The use of AFP as an oncological marker of HCC was first proposed in the 1960s, though AFP is not specific for HCC, as numerous neoplastic and non-neoplastic conditions involving the liver and other organs can cause an increase in it [15]. The gene discussed is AFP; the disease is hepatocellular carcinoma.